Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers
- Conditions
- Prion Diseases
- Interventions
- Other: blood draw
- Registration Number
- NCT02837705
- Lead Sponsor
- University of Zurich
- Brief Summary
The human Prion diseases can be classified into sporadic, acquired and inherited forms. Inherited forms usually manifest in higher age so there have to be factors preventing Prion propagation in young mutation carriers. Antibodies against the flexible tail of Prions have been shown to be protective in mice. The investigators intend to screen mutation carriers and controls for the presence of Prion autoantibodies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 213
- Relatives of patients of genetic Prion diseases
- Obtained informed consent
- No informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description carriers of a mutation in the Prion gene blood draw Carriers of a mutation in the Prion gene who are either symptomatic or pre-symptomatic and who do either know or not know their mutation status. family members of carriers of a mutation in the Prion gene blood draw Relatives of confirmed PrP mutation carriers who carry two wild type alleles.
- Primary Outcome Measures
Name Time Method Anti-Prion protein autoantibody levels Baseline, up to 90 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
CJD Foundation Israel
🇮🇱Pardés H̱anna Karkur, Israel
Istituto di Ricerche Farmacologiche
🇮🇹Milano, Italy
Slovak Medical University
🇸🇰Bratislava, Slovakia
Institute of Neuropathology
🇨🇭Zürich, Switzerland
Medical University Graz
🇦🇹Graz, Austria
University Medical Center Göttingen
🇩🇪Göttingen, Germany
UCSF Memory and Aging Center
🇺🇸San Francisco, California, United States